## Brilliant Violet 421™ anti-human CD64

Catalog # / Size: 2125095 / 25 tests

2125100 / 100 tests

Clone:

Isotype: Mouse IgG1, κ

Human rheumatoid synovial fluid cells Immunogen:

and fibronectin-purified monocytes.

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and

unconjugated antibody.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and BSA

(origin USA).

Workshop **Number:**  VI MA36

Concentration: Lot-specific



Human peripheral blood monocytes were stained with CD64 (clone 10.1) Brilliant Violet 421™ (filled histogram) or mouse IgG1 Brilliant Violet 421<sup>™</sup> isotype control (open

histogram).

## **Applications:**

Flow Cytometry **Applications:** 

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application** Notes:

Clone 10.1 recognizes the EC3 epitope of CD64. Additional reported applications (for the relevant formats) include: blocking of human IgG3 and murine IgG2a binding to FcyRl<sup>2,5,6,11</sup> and immunohistochemical staining of acetone-fixed frozen tissue sections<sup>12</sup>.

**Application References:** 

1. McMichael A, et al. Eds. 1987. Leucocyte Typing III. Oxford University Press. New York.

2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York, p. 874.

3. Kishimoto T, et al. Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products.

- 4. Holl V, et al. 2004. J. Immunol. 173:6274.
- 5. Hober D, et al. 2002. J. Gen. Virol. 83:2169.
- 6. Cho HJ, et al. 2007. Physiol Genomics 149:60.
- 7. van Tits L, et al. 2005. Arterioscler Thromb Vasc Biol. 25:717. PubMed
- 8. Bruhns P, et al. 2008. Blood 113:3716. PubMed
- 9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 10. Carter DL, et al. 1999. Cytometry 37:41. (FC)
- 11. Dougherty GJ, et al. 1987. Eur. J. Immunol. 17:1453.
- 12. Blom AB, et al. 2003. Arthritis Rheum. 48(4):1002-14. (IHC)

**Description:** CD64 is a 72 kD single chain type I glycoprotein also known as  $Fc\gamma RI$  and FcRI.

CD64 is a member of the immunoglobulin superfamily and is expressed on monocytes/macrophages, dendritic cells, and activated granulocytes. The expression can be upregulated by IFN-y stimulation. CD64 binds IgG immune complex. It plays a role in antigen capture, phagocytosis of IgG/antigen

complexes, and antibody-dependent cellular cytotoxicity (ADCC).

**Antigen** 

1. Hulett M, et al. 1994. Adv. Immunol. 57:1.

References: 2. van de Winkel J, et al. 1993. Immunol. Today 14:215.